Vinciane Pirard | Medical - SAI, Chair of IRDiRC Companies Constituent Committee (CCC)
Sanofi

Pre-congress workshops @ 14:00

Early Diagnosis – What’s Needed to Make Change Happen?

Moving beyond isolated advocacy to accelerate diagnosis, this workshop will holistically explore how early diagnosis fits within the rare disease ecosystem from development of diagnostic technologies, to care pathways and policy frameworks.  It will be based on a three-part discussion to:

- Move beyond purely technical debates

- Elicit a range of opinions and different practices 

- Align with European policy developments in rare diseases.

Moderator: Vinciane Pirard, Medical - SAI, Chair of IRDiRC Companies Constituent Committee (CCC), Sanofi

×

Vinciane Pirard / Early Diagnosis – What’s Needed to Make Change Happen?

Vinciane Pirard, Medical - SAI, Chair of IRDiRC Companies Constituent Committee (CCC),
Sanofi

Vinciane Pirard, MD Vinciane Pirard is a Medical Doctor trained at UCLouvain in Belgium, with an extensive career in the pharmaceutical industry dedicated to rare diseases since joining Genzyme in 2002. She currently serves as Medical Affairs Rare Diseases – Scientific Advocacy and Insights Lead...

CloseMore

Moderator: Karen Facey, Senior HTA Advisor, University of Edinburgh

×

Karen Facey / Early Diagnosis – What’s Needed to Make Change Happen?

Karen Facey, Senior HTA Advisor,
University of Edinburgh

Karen Facey worked as a senior statistician in Pharma and medicines regulation before moving to Scotland in 2000 to setup their first national HTA agency. Since 2003 she has been an independent consultant working with all stakeholders on matters relating to HTA in Europe and Canada, with special...

CloseMore

Alessandra Ferlini, Director of the Medical Genetics Section & Unit, University of Ferrara

×

Alessandra Ferlini / Early Diagnosis – What’s Needed to Make Change Happen?

Alessandra Ferlini, Director of the Medical Genetics Section & Unit,
University of Ferrara

Alessandra Ferlini, born in Bologna, is a medical geneticists and neurologist, associate professor in medical genetics, and head of the Medical Genetics Unit at the University of Ferrara (Italy). She is also Honorary visiting professor at the University College London from 2015. She achieved her...

CloseMore

Gulcin Gumus, Research and Policy Senior Manager, EURORDIS

Alicia Be, Senior Account Manager, FIPRA International

Day 1 @ 17:10

Screen4care EU IHI project and genomic newborn screening: mid-term results and future plans

• Screen4care EU IHI project is a collaborative effort aimed at implementing precision medicine in healthcare.
• Genomic newborn screening is a key component of this project, focusing on early detection and prevention of genetic disorders in infants.
• Mid-term results of the project show promising outcomes in terms of early diagnosis and personalized treatment plans for newborns.
• Future plans include expanding the screening program to reach more newborns and integrating genomic data into routine clinical practice.

Alessandra Ferlini, Director of the Medical Genetics Section & Unit, University of Ferrara

×

Alessandra Ferlini / Screen4care EU IHI project and genomic newborn screening: mid-term results and future plans

Alessandra Ferlini, Director of the Medical Genetics Section & Unit,
University of Ferrara

Alessandra Ferlini, born in Bologna, is a medical geneticists and neurologist, associate professor in medical genetics, and head of the Medical Genetics Unit at the University of Ferrara (Italy). She is also Honorary visiting professor at the University College London from 2015. She achieved her...

CloseMore

Vinciane Pirard, Medical - SAI, Chair of IRDiRC Companies Constituent Committee (CCC), Sanofi

×

Vinciane Pirard / Screen4care EU IHI project and genomic newborn screening: mid-term results and future plans

Vinciane Pirard, Medical - SAI, Chair of IRDiRC Companies Constituent Committee (CCC),
Sanofi

Vinciane Pirard, MD Vinciane Pirard is a Medical Doctor trained at UCLouvain in Belgium, with an extensive career in the pharmaceutical industry dedicated to rare diseases since joining Genzyme in 2002. She currently serves as Medical Affairs Rare Diseases – Scientific Advocacy and Insights Lead...

CloseMore